

IN THE UNITED STATES PATENT AND TRADEMARK OFFICECertificate of Transmission

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (571) 270 - 9877 on 7/31/06
 Total pages in this transmission: 2

Gudrun E. Huckett
 Gudrun E. Huckett, Patent Agent

In the application of: Gerolf Zimmermann et al.

Serial Number: 10/540,215

Intern. Filing Date: 12/19/2003 (PCT/DE03/04293)

Title: Method and Means for Determining Specific Conditions or Changes in the Uterine Epithelium and in the Epithelium of other Organs

ATTN: KAREN WILLIAMS
 PCT/DO/EO National Stage Paralegal Specialist
 Commissioner for Patents
 Alexandria, VA 22313

Supplemental Response to Notice to Comply with Requirements for Patent Applications**Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures**

In response to the office notice dated July 25, 2006, it is herewith stated that:

The content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.1825(d).

Authorization is herewith given to charge fees or shortages in fees required during prosecution of this application and not paid by other means to USPTO deposit account 50-1199.

Respectfully submitted on July 31, 2006,

Gudrun E. Huckett
 Ms. Gudrun E. Huckett, Ph.D.
 Patent Agent, Registration No. 35,747
 Lönssstr. 53
 42289 Wuppertal, GERMANY
 Telephone: 49-202-257-0371
 Facsimile: 49-202-257-0372
 gudrun.draudt@t-online.de

GEH.: copy of Fax Notice received 31 July 2006

Draudt

Von: Williams, Karen [Karen.Williams@USPTO.GOV]
Gesendet: Tuesday, July 25, 2006 4:56 PM
An: gudrun.draudt@t-online.de
Betreff: PCT national application: 10/540215 Docket # 00401P0004W0US

In your fax response, submitted on 21 Mar 2006 to the PCT/DO/EO/922 notice (Notification to Comply with Requirements for Patent Applications containing Nucleotide and/or Amino Acid Sequence Disclosures), the CRF diskette was received, but not the CRF statement.

According to PCT rules:
 "A statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d)."

Please fax the aforementioned statement to:

Karen Williams
 PCT/DO/EO National Stage
 Paralegal Specialist
 (571) 270-9877 fax
 (703) 308-9140, ext. 213

